Related Experiment Video
Updated: Jan 9, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
[Overview of CAR-T cell therapy : What the radiologist should know]
Mirjam Gerwing1, Michel Eisenblätter2
1Universitätsinstitut für Diagnostische und Interventionelle Radiologie, Med. Fakultät und Universitätsklinikum OWL, Klinikum Lippe, Universität Bielefeld, Röntgenstraße 18, 32756, Detmold, Deutschland. Mirjam.Gerwing@klinikum-lippe.de.
Clinical Issue:
CAR-T cell therapy is complex and is now offered at a growing number of oncology centers in Germany. In addition to the initial CAR-T cell treatment, several advances and complementary therapies are available, which radiologists should be familiar with to properly evaluate treatment response and detect side effects early.
Standard Treatment:
In hemato-oncologic diseases, combinations of chemotherapy and targeted therapies are usually administered.
Treatment Innovations:
CAR-T-cell therapy combined with complementary immunotherapies.
Diagnostic Work-Up:
For current indications, cross-sectional imaging-typically positron emission tomography/computed tomography-is used for staging and for evaluating therapy response.
Performance:
The response rate is approximately 66.4% (25.5-90.9%).
Achievements:
CAR-T cell therapy represents a new era in immunotherapy, and its recent advances mark a significant innovation in oncologic treatment.
Practical Recommendations:
Radiologists should understand the principles of CAR-T cell therapy in order to accurately assess treatment response and recognize early signs of potential side effects.
